The PROSTACT trial will compare two arms:
Group A: Two single intravenous (IV) injections of 76 mCi each (equivalent to a 45 mCi/m2 dose in a standard 1.7m2 individual) of 177Lu-DOTA- rosopatamab, given 14 days apart, plus best SoC
Group B: Best SoC.
What exactly is best SoC? That's where things get interesting.
"Investigational agents, any form of anti-neoplastic regimens including chemotherapy, platinum based anti-neoplastic drugs, poly adenosine diphosphate ribose polymerase (PARP) inhibitors, other systemic radioisotopes, and hemi-body radiotherapy are excluded from use as best SoC. Use of NAADs, such as abiraterone or enzalutamide, is permitted."
They've ruled out Cabazitaxel from the control arm, this a horrible control arm. Who will want to be in a control that prevents you from taking a lot of life prolonging drugs? There will be a lot of drop outs from the control arm.
- Forums
- ASX - By Stock
- Problem with ProstACT Clinical Trial
The PROSTACT trial will compare two arms:Group A: Two single...
-
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TLX (ASX) to my watchlist
|
|||||
Last
$19.54 |
Change
0.345(1.80%) |
Mkt cap ! $6.478B |
Open | High | Low | Value | Volume |
$19.13 | $19.62 | $19.01 | $8.305M | 428.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 788 | $19.53 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.54 | 639 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 312 | 19.570 |
12 | 1152 | 19.560 |
13 | 1282 | 19.550 |
14 | 1902 | 19.540 |
11 | 1709 | 19.530 |
Price($) | Vol. | No. |
---|---|---|
19.580 | 507 | 12 |
19.590 | 1189 | 11 |
19.600 | 1542 | 12 |
19.610 | 1219 | 12 |
19.620 | 1982 | 8 |
Last trade - 13.12pm 19/08/2024 (20 minute delay) ? |
Featured News
TLX (ASX) Chart |